Table of Contents
Cardiovascular Psychiatry and Neurology
Volume 2012, Article ID 970108, 7 pages
http://dx.doi.org/10.1155/2012/970108
Research Article

Smoking Cessation Intervention in a Cardiovascular Hospital Based Clinical Setting

1Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, Canada L8S 4L8
2Population Genomics Program, McMaster University, Hamilton, ON, Canada L8S 4K1
3Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada L8S 4K1
4Mood Disorders Program, St. Joseph's Healthcare Hamilton, 100 West 5th Street, Hamilton, ON, Canada L8N 3K7
5Hamilton General Hospital, Hamilton Health Sciences, Hamilton, ON, Canada L8L 2X2
6Population Health Research Institute, Hamilton, ON, Canada L8L 2X2
7Department of Medicine, McMaster University, Hamilton, ON, Canada L8S 4L8

Received 29 May 2012; Accepted 14 September 2012

Academic Editor: Heimo Viinamaki

Copyright © 2012 Zainab Samaan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. WHO, “WHO report on the global tobacco epidemic, 2009: implementing smoke-free environments,” Tech. Rep., WHO, Geneva, Switzerland, 2009. View at Google Scholar
  2. Canadian Tobacco Use Monitoring Survey (CTUMS).
  3. R. Doll, R. Peto, J. Boreham, and I. Sutherland, “Mortality in relation to smoking: 50 Years' observations on male British doctors,” British Medical Journal, vol. 328, no. 7455, pp. 1519–1528, 2004. View at Google Scholar · View at Scopus
  4. Z. A. K. Frosch, L. C. Dierker, J. S. Rose, and R. J. Waldinger, “Smoking trajectories, health, and mortality across the adult lifespan,” Addictive Behaviors, vol. 34, no. 8, pp. 701–704, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. N. L. Benowitz, “Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics,” Annual Review of Pharmacology and Toxicology, vol. 49, pp. 57–71, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. N. L. Benowitz, “Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction,” Clinical Pharmacology and Therapeutics, vol. 83, no. 4, pp. 531–541, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. Monitoring the Ontario Tobacco Strategy. Smoking Cessation in Ontario 1998/99-Current Trends, Interventions and Initiatives, 2000, http://www.otru.org/special_reports.html.
  8. P. S. Yusuf, S. Hawken, S. Ôunpuu et al., “Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study,” The Lancet, vol. 364, no. 9438, pp. 937–952, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. R. West and J. Stapleton, “Clinical and public health significance of treatments to aid smoking cessation,” European Respiratory Review, vol. 17, no. 110, pp. 199–204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. N. A. Rigotti, M. R. Munafo, and L. F. Stead, “Smoking cessation interventions for hospitalized smokers: a systematic review,” Archives of Internal Medicine, vol. 168, no. 18, pp. 1950–1960, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. E. J. Mills, P. Wu, D. Spurden, J. O. Ebbert, and K. Wilson, “Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis,” Harm Reduction Journal, vol. 6, no. 1, p. 25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. J. Eisenberg, K. B. Filion, D. Yavin et al., “Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials,” Canadian Medical Association Journal, vol. 179, no. 2, pp. 135–144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. L. F. Stead, R. Perera, C. Bullen, D. Mant, and T. Lancaster, “Nicotine replacement therapy for smoking cessation.,” Cochrane Database of Systematic Reviews, no. 1, p. CD000146, 2008. View at Google Scholar · View at Scopus
  14. D. E. Jorenby, S. J. Leischow, M. A. Nides et al., “A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation,” New England Journal of Medicine, vol. 340, no. 9, pp. 685–691, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Rovina, I. Nikoloutsou, G. Katsani et al., “Effectiveness of pharmacotherapy and behavioral interventions for smoking cessation in actual clinical practice.,” Therapeutic advances in respiratory disease, vol. 3, no. 6, pp. 279–287, 2009. View at Google Scholar · View at Scopus
  16. C. T. Bolliger, J. P. Zellweger, T. Danielsson et al., “Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety,” British Medical Journal, vol. 321, no. 7257, pp. 329–333, 2000. View at Google Scholar · View at Scopus
  17. E. Beard, A. Mcneill, P. Aveyard, J. Fidler, S. Michie, and R. West, “Use of nicotine replacement therapy for smoking reduction and during enforced temporary abstinence: a national survey of English smokers,” Addiction, vol. 106, no. 1, pp. 197–204, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Kroenke, R. L. Spitzer, and J. B. W. Williams, “The patient health questionnaire-2: validity of a two-item depression screener,” Medical Care, vol. 41, no. 11, pp. 1284–1292, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. K. O. Fagerstrom and N. G. Schneider, “Measuring nicotine dependence: a review of the fagerstrom tolerance questionnaire,” Journal of Behavioral Medicine, vol. 12, no. 2, pp. 159–182, 1989. View at Google Scholar · View at Scopus
  20. S. S. Anand, F. Razak, A. D. Davis et al., “Social disadvantage and cardiovascular disease: development of an index and analysis of age, sex, and ethnicity effects,” International Journal of Epidemiology, vol. 35, no. 5, pp. 1239–1245, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Treasure, “Motivational interviewing,” Advances in Psychiatric Treatment, vol. 10, no. 5, pp. 331–337, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. W. R. Miller and S. Rollnick, Motivational Interviewing: Preparing People for Change, 2002.
  23. V. Lemmens, A. Oenema, I. K. Knut, and J. Brug, “Effectiveness of smoking cessation interventions among adults: a systematic review of reviews,” European Journal of Cancer Prevention, vol. 17, no. 6, pp. 535–544, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. N. Dawood, V. Vaccarino, K. J. Reid, J. A. Spertus, N. Hamid, and S. Parashar, “Predictors of smoking cessation after a myocardial infarction: Te role of institutional smoking cessation programs in improving success,” Archives of Internal Medicine, vol. 168, no. 18, pp. 1961–1967, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. FDA drug safety communication: Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease, 2011, http://www.fda.gov/Drugs/DrugSafety/ucm259161.htm.